Dupixent Gains EU Approval as First Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade
Dupixent; chronic spontaneous urticaria (CSU); EU approval; Sanofi; Regeneron; monoclonal antibody; IL-4; IL-13; CUPID phase 3 trials; type 2 inflammation
BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition
BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology
Novo Nordisk’s Amycretin Significantly Reduces Weight and Blood Sugar in Phase 2 Type 2 Diabetes Trial
Novo Nordisk; Amycretin; Type 2 diabetes; Weight loss; HbA1c reduction; GLP-1 agonist; Amylin receptor agonist; Phase 2 clinical trial; Subcutaneous administration; Oral administration
Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory
Novartis; layoffs; Switzerland; Stein facility; pharmaceutical manufacturing; restructuring; Schweizerhalle investment
Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect
Inflation Reduction Act; SCOTUS; drug price negotiation; AstraZeneca; Medicare; pharmaceutical lawsuits; Fifth Amendment; supreme court petition; Farxiga; Centers for Medicare & Medicaid Services; price controls
FDA’s Pazdur Raises Concerns Over Legality of National Priority Voucher Program Amid Internal Disagreement
FDA; Pazdur; Commissioner’s National Priority Voucher; CNPV; legality; internal disagreement; tumor board; Tidmarsh; drug approval process
ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis
ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials
FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients
Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation
Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)
agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition